Literature DB >> 25175829

Why is there so much therapy-related AML and MDS and so little therapy-related CML?

Robert Peter Gale1, Lynn Hlatky2, Rainer K Sachs3, Tomas Radivoyevitch4.   

Abstract

Entities:  

Keywords:  DNA-damaging drugs; Radiation; Secondary leukemia; Therapy-related leukemia

Mesh：

Substances：

Year:  2014        PMID： 25175829     DOI： 10.1016/j.leukres.2014.08.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  4 in total

1.  Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Authors:  T Radivoyevitch; R K Sachs; R P Gale; R J Molenaar; D J Brenner; B T Hill; M E Kalaycio; H E Carraway; S Mukherjee; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2015-09-22       Impact factor: 11.528

2.  Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Authors:  N Gunnarsson; M Höglund; L Stenke; S Wållberg-Jonsson; F Sandin; M Björkholm; A Dreimane; M Lambe; B Markevärn; U Olsson-Strömberg; H Wadenvik; J Richter; A Själander
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

3.  A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma.

Authors:  Hyunji Choi; Sung Ran Cho; Dahae Yang; Woonhyoung Lee; Hyunyong Hwang; Ho Sup Lee; Da Jung Kim; Taeyun Kim; Mi Hyang Kim
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

4.  Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.

Authors:  Amer M Zeidan; Jessica B Long; Rong Wang; Xin Hu; James B Yu; Scott F Huntington; Gregory A Abel; Sarah S Mougalian; Nikolai A Podoltsev; Steven D Gore; Cary P Gross; Xiaomei Ma; Amy J Davidoff
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.